This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Concert Pharmaceuticals Croissance future
Future contrôle des critères 2/6
Informations clés
38.9%
Taux de croissance des bénéfices
43.3%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.9% |
| Taux de croissance des recettes | 54.9% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Low |
| Dernière mise à jour | 06 Mar 2023 |
Mises à jour récentes de la croissance future
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 96 | -69 | N/A | -86 | 2 |
| 12/31/2024 | 29 | -129 | N/A | -140 | 2 |
| 12/31/2023 | 18 | -137 | N/A | -78 | 3 |
| 12/31/2022 | 0 | -122 | N/A | N/A | 3 |
| 9/30/2022 | 32 | -127 | -110 | -110 | N/A |
| 6/30/2022 | 33 | -125 | -103 | -102 | N/A |
| 3/31/2022 | 33 | -95 | -67 | -67 | N/A |
| 12/31/2021 | 33 | -80 | -55 | -55 | N/A |
| 9/30/2021 | 1 | -66 | -45 | -45 | N/A |
| 6/30/2021 | 2 | -59 | -47 | -47 | N/A |
| 3/31/2021 | 8 | -77 | -72 | -72 | N/A |
| 12/31/2020 | 8 | -75 | -69 | -69 | N/A |
| 9/30/2020 | 8 | -73 | -68 | -68 | N/A |
| 6/30/2020 | 6 | -71 | -64 | -63 | N/A |
| 3/31/2020 | 0 | -77 | -66 | -65 | N/A |
| 12/31/2019 | 1 | -78 | -49 | -49 | N/A |
| 9/30/2019 | 1 | -79 | -50 | -49 | N/A |
| 6/30/2019 | 1 | -79 | -47 | -45 | N/A |
| 3/31/2019 | 1 | -73 | -40 | -37 | N/A |
| 12/31/2018 | 11 | -56 | -51 | -48 | N/A |
| 9/30/2018 | 11 | -41 | -41 | -39 | N/A |
| 6/30/2018 | 11 | 104 | 104 | 106 | N/A |
| 3/31/2018 | 11 | 104 | 104 | 105 | N/A |
| 12/31/2017 | 0 | 95 | 103 | 104 | N/A |
| 9/30/2017 | 0 | 89 | 98 | 99 | N/A |
| 6/30/2017 | 0 | -50 | -46 | -45 | N/A |
| 3/31/2017 | 0 | -50 | -45 | -44 | N/A |
| 12/31/2016 | 0 | -51 | -46 | -45 | N/A |
| 9/30/2016 | 10 | -38 | -33 | -33 | N/A |
| 6/30/2016 | 12 | -35 | N/A | -30 | N/A |
| 3/31/2016 | 15 | 19 | N/A | 20 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: CNCE is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: CNCE is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: CNCE is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: CNCE's revenue (54.9% per year) is forecast to grow faster than the US market (7% per year).
Croissance élevée des revenus: CNCE's revenue (54.9% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if CNCE's Return on Equity is forecast to be high in 3 years time